乐观
$195.33
情景价格
$71.110
-1.515 (-2.13%)收盘时
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
Inspire Medical Systems is currently not a strong buy due to its recent price decline and mixed analyst ratings. The current price is $68.79, with a forward P/E of 59.17 indicating high valuation expectations. The RSI is at 47.165, suggesting the stock is neither overbought nor oversold, which may indicate a wait-and-see approach. The main risk is the significant year-to-date change of -25.45%, reflecting potential volatility ahead.
RBC Capital
$75
2026-10-01
RBC Capital
2026-10-01
目标价
$75
Freedom Broker
$97
2026-09-21
Freedom Broker
2026-09-21
目标价
$97
Stifel
$80
2026-09-11
Stifel
2026-09-11
目标价
$80
Mizuho
$65
2026-08-04
Mizuho
2026-08-04
目标价
$65
JPMorgan
$60
2026-08-04
JPMorgan
2026-08-04
目标价
$60
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Inspire Medical Systems to Present at Wells Fargo Healthcare Conference

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems Reports Strong Q2 Performance and Upgrades Guidance

Inspire Medical Systems Q2 2026 Earnings Beat Expectations

Inspire Medical Systems Reports Return to Profitability in Q2
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Inspire Medical Systems is currently not a strong buy due to its recent price decline and mixed analyst ratings. The current price is $68.79, with a forward P/E of 59.17 indicating high valuation expectations. The RSI is at 47.165, suggesting the stock is neither overbought nor oversold, which may indicate a wait-and-see approach. The main risk is the significant year-to-date change of -25.45%, reflecting potential volatility ahead.
5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。